'Coronil won't be sold in Maha without certification'

Sale of Coronil will not be allowed in Maharashtra without certification: Home Minister Anil Deshmukh

The statement came a day after the Indian Medical Association (IMA) expressed shock over the 'blatant lie of WHO certification'

Baba Ramdev releases the scientific research papers on the Patanali medicine for Covid-19. Credit: PTI Photo

The Maharashtra government has decided not to allow Coronil, which has been manufactured by the Baba Ramdev-founded Patanjali Ayurveda.

The Uddhav Thackeray-led Maha Vikas Aghadi government pointed out that the Indian Medical Association (IMA) has questioned the trials while the World Health Organisation (WHO) refuted the claims.

“The IMA has questioned the said 'clinical trials' of Coronil and WHO refuted the false claims made by Patanjali Ayurveda for giving any certificate regarding its effectiveness for Covid-19 treatment,” state home minister Anil Deshmukh said.

Read: IMA 'shocked' over Patanjali’s claim on Coronil; demands explanation from Harsh Vardhan

“Launching such a drug hurriedly and being endorsed by two senior Central Union Ministers is highly deplorable. Selling of Coronil without proper certification from competent health organizations like WHO, IMA and others will not be allowed in Maharashtra,” he added.

"The #IMA has questioned the said `clinical trials' of #Coronil & WHO refuted the false claims made by #Patanjali Ayurveda for giving any certificate regarding its effectiveness for #Covid19 treatment," Deshmukh said.

 

"...selling of #Coronil without proper certification from competent health organizations like #WHO, #IMA and others will not be allowed in Maharashtra," the minister said.

However, Patanjali's managing director Acharya Balkrishna later said "We want to clarify to avoid confusion that our WHO GMP compliant COPP certificate to Coronil is issued by DCGI, Government of India" and "WHO do not approve or disapprove any drugs".

Get a round-up of the day's top stories in your inbox

Check out all newsletters

Get a round-up of the day's top stories in your inbox